ASLAN Pharmaceuticals Limited
ASLN · NASDAQ
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $12,000 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $12,000 |
| % Margin | – | – | – | 100% |
| R&D Expenses | $5,895 | $9,601 | $7,242 | $11,597 |
| G&A Expenses | $3,396 | $3,246 | $3,180 | $2,767 |
| SG&A Expenses | $3,396 | $3,246 | $3,180 | $2,767 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $36 | $0 | $0 | $0 |
| Operating Expenses | $9,291 | $12,846 | $10,422 | $14,364 |
| Operating Income | -$9,291 | -$12,846 | -$10,422 | -$2,364 |
| % Margin | – | – | – | -19.7% |
| Other Income/Exp. Net | -$628 | -$626 | $740 | $537 |
| Pre-Tax Income | -$9,919 | -$13,472 | -$9,681 | -$1,827 |
| Tax Expense | $0 | $40 | $28 | $58 |
| Net Income | -$9,919 | -$13,512 | -$9,709 | -$1,886 |
| % Margin | – | – | – | -15.7% |
| EPS | -2.12 | -3.12 | -2.24 | -0.44 |
| % Growth | 32.1% | -39.3% | -409.1% | – |
| EPS Diluted | -2.12 | -3.12 | -2.24 | -0.44 |
| Weighted Avg Shares Out | 4,668 | 4,321 | 4,301 | 4,111 |
| Weighted Avg Shares Out Dil | 4,668 | 4,321 | 4,301 | 4,111 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $10 | $1 | $69 |
| Interest Expense | $666 | $993 | $1,132 | $1,127 |
| Depreciation & Amortization | $43 | $44 | $1,872 | $1,664 |
| EBITDA | -$9,253 | -$12,436 | -$8,550 | -$700 |
| % Margin | – | – | – | -5.8% |